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The use of neurotrophic factors to treat multiple sclerosis
(MS), a spontaneous inflammatory demyelinating disease of
young adults, seems intuitively appealing: the process entails
death of cellular constituents of the central nervous system
(CNS), including oligodendroglia and neurons as well as
damage to myelin (the hallmark of MS). It appears that de-
mise of these neural cells, some of which are considered
irreplaceable, results in part from the consequences of
chronic inflammatory destruction of the myelin membrane.
This conclusion comes from several lines of evidence: most
persuasive is the axonal pathology observed in mutant mice
deficient for the proteolipid protein of CNS myelin (1). By
analogy, the ruin of demyelinated axons in the CNS of pa-
tients with MS is attributed in part to loss of the protective
and trophic influences of myelin itself (2, 3). It also appears
likely that oligodendroglia, challenged to remyelinate re-
peatedly within the inflammatory microenvironment of the
MS lesion, undergo extensive cell death (4). Therefore, re-
myelination is viewed as a critical neuroprotective event,
protecting axons from lysis and restoring normal oligoden-
drocyte physiology.
Furthermore, remyelination, different from other forms
of CNS regeneration in mammals, seems tantalizingly feasi-
ble: it has long been known that remyelination of denuded
axons can be vigorous and effective in the early phases of
MS (5). Remyelination gives rise to structures termed
“shadow plaques” in which axons are ensheathed by short-
ened, thinned myelin internodes that are nonetheless highly
functional. The failure of remyelination during chronic MS
has been attributed to insufficient numbers or impaired dif-
ferentiation of resident oligodendrocyte precursors.
 
Work in vitro
 
 
 
and
 
 
 
in vivo
 
 
 
has produced a substantial
body of knowledge of the growth factors required for pro-
liferation and differentiation of oligodendroglia. Not sur-
prisingly, many of the trophic factors (including nerve
growth factor [NGF], ciliary neurotrophic factor, platelet-
derived growth factor, basic fibroblast growth factor, neu-
rotrophin-3, and insulin-like growth factor [IGF]-1]) that
support oligodendrocyte survival or proliferation also act
towards subpopulations of neurons. It could be hoped that
provision of neural growth factors to the CNS under in-
flammatory demyelinative siege could aid both oligoden-
droglia and neurons to survive.
In this context, preclinical treatment trials of various
neurotrophins have been undertaken. In most cases, the hy-
pothesis to be tested was that trophic support for oligoden-
droglia or their progenitors might promote remyelination.
In the main, these studies were conducted in rodent models
of MS, including experimental autoimmune encephalomy-
elitis (EAE) and virus-induced demyelination, caused by
Theiler’s murine encephalomyelitis virus (TMEV). It has
been a formidable technical challenge to demonstrate that
individual factors could promote remyelination in these sys-
tems. In part, the reason for this difficulty lies in the sharing
of growth factors and/or cytokines between the immune
and nervous systems. Therefore, agents that are predicted to
act solely on neurons or oligodendroglia frequently exhibit
immunomodulatory activities as well. This attribute of the
protein factors studied in parallel by immunologists and
neurobiologists has been intriguing and perplexing experi-
mentalists for more than a decade.
There is another level of complexity imposed by the
multistage disease process of EAE, during which demyeli-
nation (destruction) is succeeded by remyelination (tissue
repair). Remyelination, as quantitated at the endpoint of an
EAE experiment, reflects the aggregate of destruction and
repair. Therefore, it can be impossible to disentangle the re-
straint of inflammation from the promotion of remyelina-
tion or other forms of tissue repair. In a head-to-head com-
parison, two agents, one of which produces a purely
antiinflammatory effect while the other exhibits solely re-
myelinative properties, may pari passu generate identical
net increases in remyelination.
An appreciation of the challenges that complicate experi-
mental use of neurotrophins in EAE can be obtained by re-
viewing the results of studies using IGF-1 to treat this
model disease. IGF-1 has many attributes of a promising re-
myelinative agent: it is expressed vigorously and early in
detergent-mediated models of demyelination, before the
onset of remyelination (6). Further, IGF-1 promotes remy-
elination in organotypic neural cultures in vitro
 
 
 
after myelin
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lysis, mediated by antibodies and complement (7). Upon
administration to Lewis rats with acute passive-transfer
EAE, IGF-1 produced beneficial histological and clinical
outcomes that were initially proposed to result from en-
hanced remyelination (8). However, further analysis indi-
cated that effects on the inflammatory component of acute
EAE, rather than myelin repair, determined the therapeutic
benefit of IGF-1 administration (9). Subsequent experi-
ments in chronic murine EAE also demonstrated benefits
that appeared to result from reduced inflammatory tissue
injury (10). Somewhat disconcertingly, it was recently
shown that minor variations in timing or dose of IGF-1
could switch results of treating mice with chronic EAE
from beneficial to deleterious outcomes (11).
Villoslada et al. in this issue provide evidence that con-
tinuous intracerebroventricular (ICV) infusions of recombi-
nant human NGF reduced the severity of EAE in nonhu-
man primates (12). Use of the marmoset model for these
studies imposes both advantages and disadvantages for gen-
eralizing the results and is worthy of comment. The use of
the New World primate species 
 
Callithrix jacchus 
 
in EAE
was developed by Hauser and Genain during the past de-
cade, and the model has been continuously refined as its at-
tributes emerged (13). Evident benefits of the model in-
cluded salient similarities to MS: chronicity with relapse,
primary inflammatory demyelination, and changes on mag-
netic resonance imaging (MRI) brain scans. The naturally
occurring bone marrow chimerism between littermate
Figure 1. Distribution of NGF after ICV administration. (A) A coronal section of marmoset brain at the level of the thalamus, stained with methylene
blue. Indicated for localization are the lateral geniculate nucleus, the brachium conjunctivum, and the pons. The arrow shows the trajectory of the ICV
cannula, terminating in the lateral ventricle. NGF (filled red circles) is delivered from the pump into the ventricle. The box indicates the region shown in
the cartoon in B. (B) The brain parenchyma is shown in blue, with NGF shown as filled red circles. Astrocytes are denoted by stars. After ICV adminis-
tration, NGF distributes in the subarachnoid space: the ventricle, the subarachnoid space over the cerebral convexities, and the perivascular subarachnoid
space, each of which is labeled. The pial surface (between brain parenchyma and subarachnoid space) is shown as a heavy solid line; the arachnoid mem-
brane is shown as a dashed line. 
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marmosets (fraternal twins that share placental circulatory
support in utero
 
) 
 
provided the opportunity for adoptive
transfer studies in an outbred species (14). With persistent
study, it became clear that myelin oligodendroglial glyco-
protein (MOG), a minor myelin constituent, was a major T
cell and B cell target of the encephalitogenic process in this
species, as is currently suspected in human MS (15). There
are also several problems with this model: because of their
expense and scarcity, marmosets are not used for EAE ex-
periments in the numbers with which rodent EAE experi-
mentalists are familiar. Thus, statistical power may be lost,
and in-depth follow-up mechanistic studies are not feasible.
Another less obvious obstacle is that, perhaps contrary to
expectations, adult marmosets weigh between 250 and 500 g.
For that reason, limited analysis of blood and cerebrospi-
nal fluid (CSF) from these animals can be performed. Obvi-
ously, immunological reagents that are prepared for analyz-
ing human material often, but not always, function well in
marmoset studies (
 
C. jacchus
 
 are New World monkeys, un-
like 
 
Homo sapiens sapiens
 
). However, if anti–human anti-
bodies don’t detect marmoset determinants, limited alterna-
tives are available. Genetic manipulations, so convenient
and frequently informative in mice, are not practical in
marmoset EAE experiments. Perhaps the most significant
benefit of EAE studies in nonhuman primates concerns the
direct application of reagents that are targeted against hu-
man receptors (16).
The current study (12) was founded on the hypothesis
that neurotrophin treatment could improve remyelination,
and thus clinical recovery. The early onset of the treatment
effect and its antiinflammatory mechanism were both unex-
pected. These unforeseen results could open new vistas on
the analysis and treatment of immunopathological diseases
of the CNS, including most prominently MS.
Certainly, the results reported by Villoslada et al. (12)
demonstrated impressive and convincing benefit from NGF
administration. Receiving agent in a preventive fashion
(before the onset of EAE), NGF-treated animals experi-
enced delay in EAE onset and milder disease; one marmoset
was completely protected from clinical disease while show-
ing modest histological inflammation. Five of the six treated
animals fared better than any of the controls. The immuno-
logical effects of NGF in this model were fascinating: there
was no effect on priming of antigen-specific, encephalito-
genic T cells in vitro
 
 
 
or
 
 
 
in vivo
 
 
 
and no change in produc-
tion of MOG-specific antibodies. However, NGF-treated
marmosets demonstrated a marked decrease in histological
inflammatory scores and much less demyelination.
Importantly, inflammation and demyelination in both
control and NGF-treated marmosets were concordant, ar-
guing against an effect at the level of myelin repair. Taken
together, these results suggested a change in the ability of
primed T cells to orchestrate the CNS inflammatory re-
sponse. To address the mechanism of this effect, tissue sec-
tions were analyzed for cells immunoreactive for IFN-
 
g
 
 or
IL-10. There was a significant decrease in IFN-
 
g
 
–immu-
noreactive cells and an increase in IL-10–producing cells.
Perhaps most interesting, the cells expressing IL-10 were
astrocytes, resident neuroepithelial elements. Accordingly,
it appears likely that the beneficial effect of NGF treatment
was mediated by eliciting an immunoregulatory response
from neural cells. Also of note, astrocytes were previously
shown to be the principal source of IL-10 in MS lesions,
consistent with the possibility that astrocyte IL-10 repre-
sents a CNS-intrinsic mechanism for suppressing inflamma-
tion (17).
The site of action of NGF, which was given directly
ICV, may also be addressed by these results. During contin-
uous ICV administration, high concentrations of NGF
would be present in the extracellular fluid of the perivascu-
lar subarachnoid space, which is in equilibrium with the
ventricular CSF (see Fig. 1). Therefore, potent effects on
perivascular T cells (such as the observed downregulation of
IFN-
 
g
 
) might be anticipated, given the expression of the
high-affinity NGF receptor, trkA, by T cells (reference 18;
see Fig. 2). It is also important to consider whether NGF,
delivered ICV, might diffuse or be transported across the
blood–brain barrier into the circulation, and achieve suffi-
cient concentration to act on circulating cells.
Less secure would be the potential of NGF to reach the
cells of the CNS parenchyma. It appears possible, although
far from certain, that the high expression of IL-10 by pa-
renchymal astrocytes was driven directly by NGF, suggest-
ing an effect on cells distant from the site of delivery. The
ability of NGF to stimulate astroglial production of IL-10 in
vitro
 
 
 
has not been addressed. However, it has been re-
ported that IL-10 treatment enhances NGF production by
astrocytes in culture, opening the possibility of an autoregu-
latory feed-forward circuit (19).
If NGF did not directly elicit IL-10 production by astro-
cytes, how else could one explain this observation? One al-
ternative possibility is that NGF acted on mast cells that are
bathed by CSF within the subarachnoid space, thereby elic-
iting immunosuppressive mediators such as prostanoids
(reference 20; see Fig. 2). Mast cells are an established target
for NGF in the CNS, and in some reports, the response of
these enigmatic cells is to produce immunoregulatory se-
creted factors, which could stimulate nearby parenchymal
cells (21–23). Regardless of the detailed mechanism, it is
highly intriguing to consider that NGF administration ren-
dered the CNS nonpermissive for development of im-
mune-mediated demyelinative lesions, by inducing local
mechanisms of restraining inflammatory reactions.
The implications of this study (12) clearly extend our
knowledge of the biology of NGF in CNS inflammation,
while posing new questions. Previous demonstrations that
NGF was present in the tissues of humans with MS and ro-
dents with EAE led to divergent conclusions, ranging from
speculation that NGF was a contributor to the inflamma-
tory pathology to conjecture that recovery from demyeli-
nation was attributable to NGF upregulation (24–27). In
the event, it seems that none of these formulations would
have predicted the results of treatment with NGF, sounding
a precautionary note for MS researchers.
Given these caveats, what are the practical lessons for
possible clinical application of NGF to be drawn from the 
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report by Villoslada et al. (12)? First, it should be deter-
mined if systemic administration of NGF (already used in a
short trial for diabetic neuropathy [28]) can generate bene-
ficial outcomes of this magnitude in the marmoset model.
This will be an important distinction: MS typically becomes
symptomatic at about age 30, and many experts currently
favor early and continuous treatment thereafter for life. In
that context, ICV infusions are unlikely to be feasible for
the majority of MS patients. It bears recalling that IFN-
 
b
 
was initially shown to be effective in MS by the intrathecal
route and subsequently demonstrated to have equal efficacy
when delivered by peripheral injections. However, if sys-
temic injections of NGF prove to be ineffective in modify-
ing the course of EAE, other “blue sky” alternatives may
become more attractive. Thus, this report may provide ad-
ditional impetus to use gene therapy to deliver factors such
as NGF in CNS demyelinating diseases, via genetically
modified T cells that recognize CNS determinants and pro-
duce NGF or other factors upon antigen encounter (29,
30). Second, and concurrently, it will probably be deter-
mined if the proposed cellular mechanisms of the NGF-
mediated treatment effect can be demonstrated in vitro
 
 
 
(in-
ducing IL-10 expression by astrocytes and blocking IFN-
 
g
 
production by primed antigen-stimulated T cells). Cer-
tainly, concerns that engagement of the p75 low-affinity
NGF receptor could deliver death signals to oligodendro-
cytes, raised by results of in vitro
 
 
 
studies, will need to be re-
solved (31, 32). If questions about long-term safety, effi-
cacy, and tolerability of NGF treatment of humans are
resolved satisfactorily, then the report by Villoslada et al.
(12) may represent a landmark in defining new therapeutic
strategies for MS.
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